| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
| (30) |
Priority: |
04.03.2011 US 201113041211
|
| (43) |
Date of publication of application: |
|
15.01.2014 Bulletin 2014/03 |
| (73) |
Proprietor: Annovis Bio, Inc. |
|
Berwyn, PA 19312 (US) |
|
| (72) |
Inventor: |
|
- MACCECCHINI, Maria
West Chester, PA 19380 (US)
|
| (74) |
Representative: Dehns |
|
St. Bride's House
10 Salisbury Square
London EC4Y 8JD
London EC4Y 8JD (GB) |
| (56) |
References cited: :
WO-A1-2005/089746
US-A1- 2002 094 999
|
WO-A2-2010/117727
US-A1- 2005 013 869
|
|
| |
|
|
- HAROLD W HOLLOWAY ET AL: "Posiphen and Analogs: Experimental Alzheimer Agents that
Reduce Amyloid-[beta] Peptide by Lowering Amyloid Precursor Protein Levels in Culture
and In Vivo", 42ND ANNUAL WINTER CONFERENCE ON BRAIN RESEARCH, 25 January 2009 (2009-01-25),
XP055130785, 42nd Annual Winter Conference on Brain Research
- Maria L Maccecchini ET AL: "Posiphen: Experimental Alzheimer Agent that Lowers Amyloid
Precursor Protein Levels in Culture and In Vivo", , 12 July 2009 (2009-07-12), XP055130786,
International Conference on Alzheimer's Disease Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/ICAD_Posip
hen_06-30-2009.pdf [retrieved on 2014-07-22]
- Maria Maccecchini ET AL: "Targeting Alzheimer's with Novel Therapuetics", , 11 May
2010 (2010-05-11), XP055130807, Neuroscience Network Retrieved from the Internet:
URL:http://www.qrpharma.com/pdf/2010-5-11 Alzheimers Research Today Maria Maccecchini
slides.pdf [retrieved on 2014-07-22]
- Maria L. Maccecchini: "Mechanism of Action of Posiphen : From Model to Human", , 26
January 2011 (2011-01-26), XP055130818, 44nd Annual Winter Conference on Brain Research
Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/WCBR Talk Jan 2011.pdf
[retrieved on 2014-07-22]
- KADIR A ET AL: "Long-term effect of phenserine treatment in Alzheimer patients as
assessed by PET and CSF biomarkers", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION,
ELSEVIER, NEW YORK, NY, US, vol. 5, no. 4, 1 July 2009 (2009-07-01), page P6, XP026897327,
ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2009.05.019 [retrieved on 2009-07-01]
- MACCECCHINI ET AL.: 'Posiohen lowers amyloid precursor protein and amyloid beta as
well as acetylcholinesterase levels in culture, animals and humans' INTERNATIONAL
CONFERENCE ON ALZHEIMER'S DISEASE vol. 5, no. 4, 12 July 2009, XP026253808 Retrieved
from the Internet: <URL:http://www.qrpharma.com/pdf/ICAD_Posip hen_06-30-2009.pdf>
[retrieved on 2012-05-19]
- U.S. Department Of Health And Human Services Food And Drug Administration Center For
Drug Evaluation And Research (cder): "Guidance for Industry Estimating the Maximum
Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers",
, 6 July 2005 (2005-07-06), XP055568568, Retrieved from the Internet: URL:https://www.fda.gov/downloads/Drugs/Gu
idances/UCM078932.pdf#search='guidekines+f or+industry+sfe+starting' [retrieved on
2019-03-13]
- Jack T. Rogers ET AL: "The alpha-synuclein 5'untranslated region targeted translation
blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen", Journal
of Neural Transmission, vol. 118, no. 3, 8 January 2011 (2011-01-08), pages 493-507,
XP055625613, Vienna ISSN: 0300-9564, DOI: 10.1007/s00702-010-0513-5
- D. K. Lahiri ET AL: "The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine]
Lowers Amyloid-beta Peptide Levels in Cell Culture and Mice", Journal of Pharmacology
and Experimental Therapeutics, vol. 320, no. 1, 27 June 2006 (2006-06-27) , pages
386-396, XP055130741, ISSN: 0022-3565, DOI: 10.1124/jpet.106.112102
|
|
